Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells

European Journal of Pharmacology

Volumn 727, Issue 1, 2014, Pages 167-173

  Ishima, Tamaki ^a   Fujita, Yuko ^a   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Antidepressant; Mirtazapine; Neurite outgrowth; Selective serotonin reuptake inhibitor; Serotonin and noradrenaline reuptake inhibitor; Sigma 1 receptor chaperone

Indexed keywords

ANTIDEPRESSANT AGENT; CHAPERONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SERTRALINE; SIGMA 1 OPIATE RECEPTOR; VENLAFAXINE; ANISOLE DERIVATIVE; N,N-DIPROPYL-2-(4-METHOXY-3-(2-PHENYLETHOXY)PHENYL)ETHYLAMINE MONOHYDROCHLORIDE; NERVE GROWTH FACTOR; PROPYLAMINE; SEROTONIN 1 ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; MOLECULAR DYNAMICS; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; ANIMAL; BRAIN; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; MALE; METABOLISM; NEURITE; PC12 CELL LINE; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANISOLES; ANTIDEPRESSIVE AGENTS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MOLECULAR CHAPERONES; NERVE GROWTH FACTOR; NEURITES; PC12 CELLS; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, SIGMA; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84896714691     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.064     Document Type: Article

References (47)

1. S. Benjamin, and P.M. Doraiswamy Review of the use of mirtazapine in the treatment of depression Expert Opin. Pharmacother. 12 2011 1623 1632
2. J.E. Bermack, and G. Debonnel The role of sigma receptors in depression J. Phamacol. Sci. 97 2005 317 336 (Pubitemid 40515745)
3. A. Bonnin, L. Zhang, R.D. Blakely, and P. Levitt The SSRI citalopram affects fetal thalamic axon responsiveness to netrin-1 in vitro independently of SERT antagonism Neuropsychopharmacology 37 2012 1879 1884
4. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
5. A. Cipriani, T.A. Furukawa, G. Salanti, J.R. Geddes, J.P. Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I.M. Omori, H. McGuire, M. Tansella, and C. Barbui Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
6. KF. Croom, C.M. Perry, and G.L. Plosker Mirtazapine: a review of its use in major depression and other psychiatric disorders CNS Drugs 23 2009 427 452
7. P.J. Goodnick, and B.J. Goldstein Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology J. Psychopharmacol. 12 3 Suppl B 1998 S5 20
8. P.J. Goodnick, and B.J. Goldstein Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life J. Psychopharmacol. 12 3 Suppl B 1998 S21 54
9. K. Hashimoto Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship Cent. Nerv. Syst. Agents Med. Chem 9 2009 197 204
10. K. Hashimoto Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol. Disord. Drug Targets 8 2009 470 474
11. K. Hashimoto Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression Prog. Neurobiol. 100 2013 15 29
12. K. Hashimoto, Y. Fujita, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors Neuropsychopharmacology 32 2007 514 521
13. K. Hashimoto, and T. Furuse Sigma-1 receptor agonist fluvoxamine for delirium in older adults Int. J. Geriatr. Psychiatry 27 2012 981 983
14. K. Hashimoto, and K. Ishiwata Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals Curr. Pharm. Des. 12 2006 3857 3876 (Pubitemid 44560699)
15. T. Hayashi, and T.P. Su Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders CNS Drugs 18 2004 269 284 (Pubitemid 38526712)
16. 2+ signaling and cell survival Cell 131 2007 596 610 (Pubitemid 350017760)
17. T. Hayashi, and T.P. Su An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma-1 receptor ligand Expert Opin. Ther. Targets 12 2008 45 58 (Pubitemid 351247161)
18. T. Hayashi, and T.P. Su Cholesterol at the endoplasmic reticulum: roles of the sigma-1 receptor chaperone and implications thereof in human diseases Subcell. Biochem. 51 2010 381 398
19. T. Hayashi, S.Y. Tsai, T. Mori, M. Fujimoto, and T.P. Su Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders Expert Opin. Ther. Targets 15 2011 557 577
20. I. Hindmarch, and K. Hashimoto Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered Hum. Psychopharmacol. 25 2010 193 200
21. S. Hosenbocus, and R. Chahal SSRIs and SNRIs: a review of the discontinuation syndrome in children and adolescents J. Can. Acad. Child Adolesc. Psychiatry 20 2011 60 67
22. M. Ishikawa, and K. Hashimoto The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases J. Receptor Ligand Channel Res. 3 2010 25 36
23. 11C]SA4503 Biol. Psychiatry 62 2007 878 883 (Pubitemid 47488223)
24. T. Ishima, Y. Fujita, M. Kohno, S. Kunitachi, M. Horio, Y. Takatsu, T. Minase, M. Iyo, and K. Hashimoto Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline Open Clin. Chem. J. 2 2009 7 11
25. 3 receptors PLoS One 7 2012 e37989
26. T. Ishima, M. Iyo, and K. Hashimoto Neurite outgrowth mediated by the heat shock protein HSP90α: a novel target for the antipsychotic drug aripiprazole Transl. Psychiatry 2 2012 e170
27. 3 receptors Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1656 1659
28. J.L. Katz, T.P. Su, T. Hiranita, T. Hayashi, G. Tanda, T. Kopajtic, and S.Y. Tsai A role for sigma receptors in stimulant self administration and addiction Pharmaceuticals (Basel) 4 2011 880 914
29. T. Kishi, and N. Iwata Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia Int. J. Neuropsychopharmacol. 17 2014 343 354
30. S. Kourrich, T.P. Su, M. Fujimoto, and A. Bonci The sigma-1 receptor: roles in neuronal plasticity and disease Trends Neurosci. 35 2012 762 771
31. J.A. Lieberman, F.P. Bymaster, H.Y. Meltzer, A.Y. Deutch, G.E. Duncan, C.E. Marx, J.R. Aprille, D.S. Dwyer, X.M. Li, S.P. Mahadik, R.S. Duman, J.H. Porter, J.S. Modica-Napolitano, S.S. Newton, and J.G. Csernansky Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection Pharmacol. Rev. 60 2008 358 403
32. X.H. Lu, and D.S. Dwyer Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways J. Mol. Neurosci. 27 2005 43 64 (Pubitemid 41112378)
33. T. Maurice, A. Urani, V.L. Phan, and P. Romieu The interaction between neuroactive steroids and the sigma-1 receptor function: behavioral consequences and therapeutic opportunities Brain Res. Rev. 37 2001 116 132 (Pubitemid 34020726)
34. M.L. Millan Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 110 2006 135 370
35. R. Molteni, F. Calabrese, G. Racagni, F. Fumagalli, and M.A. Riva Antipsychotic drug actions on gene modulation and signaling mechanisms Pharmacol. Ther. 124 2009 74 85
36. K. Nagao, T. Kishi, M. Moriwaki, K. Fujita, S. Hirano, Y. Yamanouchi, T. Funahashi, and N. Iwata Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder Neuropsychiatr. Dis. Treat. 9 2013 781 786
37. N. Narita, K. Hashimoto, S. Tomitaka, and Y. Minabe Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain Eur. J. Pharmacol. 307 1996 117 119 (Pubitemid 26226293)
38. C.B. Nemeroff, and M.J. Owens Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis CNS Spectr. 9 6 Suppl 4 2004 23 31 (Pubitemid 38868892)
39. T. Niitsu, M. Iyo, and K. Hashimoto Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases Curr. Pham. Des. 18 2012 875 883
40. 3 receptors and cellular signaling pathways PLoS ONE 3 2008 e2558
41. S. Okuyama, and A. Nakazato NE-100: a novel sigma receptor antagonist CNS Drug Rev. 2 1996 226 237 (Pubitemid 26256669)
42. M.J. Owens Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond J. Clin. Psychiatry 65 Suppl 4 2004 5 10
43. S.M. Stahl Not so selective serotonin selective reuptake inhibitors J. Clin. Psychiatry 59 1998 343 344 (Pubitemid 28373099)
44. T.P. Su, T. Hayashi, T. Maurice, S. Buch, and A.E. Ruoho The sigma-1 receptor chaperone as an inter-organelle signaling modulator Trends Pharmacol. Sci. 31 2010 557 566
45. M. Takebayashi, T.P. Hayashi, and T.P. Su Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants J. Pharmacol. Exp. Ther. 303 2002 1227 1237 (Pubitemid 35424409)
46. N. Watanabe, I.M. Omori, A. Nakagawa, A. Cipriani, C. Barbui, R. Churchill, and T.A. Furukawa Mirtazapine versus other antidepressive agents for depression Cochrane Database Syst. Rev. 2011 12
47. B. Williams, and D.S. Dwyer Structure-based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor J. Neurochem. 110 2009 1876 1884